R7E:FRA
Cybin Inc
€10.88
arrow_downward
-0.91%(-0.100) 1D
Sep 30, 10:00:00 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for R7E...
Open
€10.88
High
€10.88
Low
€10.88
Avg. vol.
649.00
Volume
0.00
52-wk high
€13.36
52-wk low
€3.08
No. of employees
100
Open
€10.88
High
€10.88
Low
€10.88
Avg. vol.
649.00
Volume
0.00
52-wk high
€13.36
52-wk low
€3.08
No. of employees
100
News stories
From web sources and news partners
WBOC TV
·
1 hour ago
Chilwa Announces Nasdaq Listing and Pricing of US$3.5 Million Offering
MarketBeat
·
36 minutes ago
First Northwest Bancorp (NASDAQ:FNWB) Shares Shorted: Short Interest Down 45.1% in September
Simply Wall Street
·
1 hour ago
Plug Power (PLUG) Lands 280 MW Deal And Preferred Role Across 1 GW Projects
Bloomberg.com
·
3 hours ago
Asian Stocks Eye Rough Start After US Reversal: Markets Wrap
Profile
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, deupsilocin, deudimethyltryptamine, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, deupsilocin is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
About Cybin Inc
CEO-
Employees100
Founded2019
HeadquartersToronto, Ontario, Canada
SectorPharmaceutical industry
Websitehelus.com